Male grasping basketball reflects teenage acne patients benefited as part of the AKLIEF® (trifarotene) Cream pivotal studies

Teenage acne NEARLY HALF THE PATIENTS IN AKLIEF CREAM PIVOTAL STUDIES WERE TEENS.1Facial and truncal acne negatively impacts teen patients' participation in activities they love.2

85% of people aged 12 to 25 experience some form of acne2

~50% of teens experience unfair treatment at school and negative effects on their school performance because of their acne2

39% of teens avoid participating in activities that reveal their acne2

AKLIEF Cream and teen patients with acne

  • Can provide acne relief for your teen patients who have both facial and truncal acne3
  • In clinical trials, the most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site pruritus (itching) and sunburn4

 

Teen female swimmer stretching arm represents teen acne in skin of color patients benefiting from AKLIEF® (trifarotene) Cream

Acne in Skin of Color OVER 300 PATIENTS WITH SKIN OF COLOR TOOK PART IN THE AKLIEF Cream PIVOTAL STUDIES.1

Percentage of women, by race, affected by acne5:

  • 37% Black/African American
  • 32% Hispanic/Latina
  • 30% Asian

 

AKLIEF Cream pivotal studies included over 300 skin of color patients.1

  • Proven effectiveness and tolerability for patients across a range of Fitzpatrick scale skin types6
  • Darker Fitzpatrick skin types (IV-VI) on average demonstrated equal or better tolerability with AKLIEF Cream over a 52-week long-term safety study
  • In clinical trials, the most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site pruritus (itching) and sunburn4

 

Galderma CareConnect patient savings card can help teen acne patients save money on AKLIEF® (trifarotene) Cream prescriptions

Treating acne doesn't have to break the bank.*

PATIENT SAVINGS CARD
Female serving tennis ball reflects patients with acne vulgaris can achieve clearer skin with AKLIEF® (trifarotene) Cream

HELP YOUR PATIENTS ACHIEVE
CLEARER SKIN.

PATIENT RESOURCES

*The Galderma® CAREConnect™ Program (“Program”) is brought to you by Galderma Laboratories, L.P. (“Galderma”). The Program is only available for commercially unrestricted or commercially restricted/cash paying patients. Patients who are enrolled in state or federally government-run or government-sponsored healthcare plan with a pharmacy benefit are not eligible to use the Galderma CAREConnect Patient Savings Card (“Card”). Any claim under the Program must be submitted by participating pharmacies to one of the Administrators of the Program.

 

References: 1. Tan J, Thiboutot D, Popp G, et al. Randomized phase 3 evaluation of trifarotene 50 µg/g cream treatment of moderate facial and truncal acne. J Am Acad Dermatol. 2019;80(6):1691-1699. 2. Galderma Laboratories, L.P. Burden Summary Report: Combined Facial & Truncal Acne. March 2021. 3. AKLIEF Press Release. Food and Drug Administration approval, 2019. 4. AKLIEF (trifarotene) Cream 0.005% [Prescribing Information]. Ft Worth, TX: Galderma Laboratories, L.P.; October 2019. 5. Callender VD, Alexis AF, Daniels SR, et al. Racial differences in clinical characteristics, perceptions and behaviors, and psychosocial impact of adult female acne. J Clin Aesthet Dermatol. 2014;7(7):19-31. 6. Blume-Peytavi U, Fowler J, Kemény L, et al. Long-term safety and efficacy of trifarotene 50 μg/g cream, a first-in-class RAR-γ selective topical retinoid, in patients with moderate facial and truncal acne. J Eur Acad Dermatol Venereol. 2020;34(1):166-173.

IMPORTANT SAFETY INFORMATION

Indication: AKLIEF® (trifarotene) Cream, 0.005% is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. Adverse Events: The most common adverse reactions (incidence ≥ 1%) in patients treated with AKLIEF Cream were application site irritation, application site pruritus (itching), and sunburn. Warnings/Precautions: Patients using AKLIEF Cream may experience erythema, scaling, dryness, and stinging/burning. Use a moisturizer from the initiation of treatment, and, if appropriate, depending upon the severity of these adverse reactions, reduce the frequency of application of AKLIEF Cream, suspend or discontinue use. Avoid application of AKLIEF Cream to cuts, abrasions or eczematous or sunburned skin. Use of “waxing” as a depilatory method should be avoided on skin treated with AKLIEF Cream. Minimize exposure to sunlight and sunlamps. Use sunscreen and protective clothing over treated areas when exposure cannot be avoided.

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Your use of this website is subject to our Updated Privacy Policy. Click here to read more.

Your use of this website is subject to our Updated Privacy Policy. Click here to read more.

up